Key facts
- TwoStep Therapeutics’s last known valuation is $14.5M (Mar 2024).
- It has raised $51.5M across 2 recorded rounds; the latest was Early Stage VC ($21.1M) in Jan 2026.
- Notable investors include Insight Partners (New York), NFX, Alexandria Venture Investments, 2048 Ventures, Medical Excellence Capital — 7 tracked in total.
- TwoStep Therapeutics has filed 1 Form D with the SEC, most recently Mar 2024 ($6.5M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for TwoStep Therapeutics
Funding rounds
2 roundsAbout TwoStep Therapeutics
Operator of a biotechnology company intended to develop novel tumor-targeting therapeutics for solid tumors. The company is developing a diverse pipeline of targeted cancer therapies using a unique integrin-binding agent that enables delivery of various payloads to virtually any solid tumor, enabling clients to deliver to virtually any solid tumor using a unique and modular delivery system.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2023
- Employees
- 7
- Website
- twosteptx.com/
- Ownership
- Privately Held (backing)
TwoStep Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TwoStep Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TwoStep Therapeutics in its N-PORT filings yet. We sweep new filings monthly.